From studying DNA in the lab to working with patients in clinical trials, Amgen scientists are pioneering new approaches to understanding human biology and making innovative medicines to treat disease. Join leaders at Amgen and beyond for in-depth discussions of the latest science and discoveries in our podcasts developed in collaboration with The Scientist.

Out Now: Human Data Era

By studying human genetics, scientists discovered mechanisms that, when defective, cause disease. While this type of data is powerful, additional information can provide more insight on the human condition.

In the Human Data Era podcast, Ray Deshaies, senior vice president of Global Research at Amgen, explores the potential of human data and the important transition scientists and clinicians are making to incorporate this wealth of information into drug research and development.

Launched Oct 20, 2022

Meet the Scientists    Listen Now

Episode List

Human Data: Beyond the Genome 
with Rob Lenz, M.D., Ph.D., senior vice president of Global Development at Amgen

New Connections Between Genetics and Human Disease
with Nancy Cox, Ph.D., director of the Vanderbilt Genetics Institute 

Exploring Human Data in Cardiovascular Disease 
with Narimon Honarpour, M.D., vice president of General Medicine, Global Clinical Development at Amgen

The Role of Human Diversity in Progressing Precision Medicine
with Kári Stefánsson, M.D., founder, deCODE Genetics

 

Innovating Clinical Trials

Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress.  

In this four-part series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop potential new medicines that benefit patients. 

Launched Sept 1, 2022

Meet the Scientists    Listen Here

Episode List

Operational Innovation  
with Dr. Cynthia Verst, President, Design and Delivery Innovation, R&D Solutions at IQVIA  

Real World Data in Drug Development   
with Brian D. Bradbury, D.Sc., Vice President, Center for Observational Research at Amgen 

The Right Patients  
with Dr. Ponda Motsepe-Ditshego, Vice President and Therapeutic Area Head of Global Medical, General Medicine at Amgen 

Real-World Clinical Trial Design and Execution in Oncology  
with David Raben, M.D., Vice President Global Development & Product General Manager, Oncology at Amgen 

 

The Generative Biology Revolution

Generative biology is a revolutionary approach to drug discovery and development that leverages AI and machine learning to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of drug discovery.  

In this four-part series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.  

Launched June 23, 2022

Meet the Scientists    Listen Here

Episode List

The Cresting Wave of Transformational Science 
with Alan Russell, Ph.D., vice president of Biologics  

The Protein Structure Prediction Problem 
with Mike Nohaile, Ph.D., Chief Scientific Officer, Generate Biomedicines 

Protein Design 
with David Baker, Ph.D., Institute for Protein Design, University of Washington 

Accelerating Drug Discovery 
with Suzanne Edavettal, Ph.D., executive director of Protein Engineering

Undruggable

In this five-part series, Ray Deshaies hosts conversations with leading scientists to take a deep dive into the most promising new ways to treat disease as we enter a fourth wave of innovation. Listen in to learn how the current wave of discovery, led by new types of multispecific medicines, has the potential to radically alter our concept of how drugs can work and pave the way for new solutions.

Stream all episodes


Episode List

The Next Wave of Drug Development 
with Ryan Potts, Ph.D., executive director, Research and head of Induced Proximity Platform at Amgen

The Biology of PROTACs 
with Craig Crews, Ph.D., professor of Molecular, Cellular and Developmental Biology, Yale

Discovery at the DNA Encoded Library 
with Alex Gouliaev, Ph.D., vice president, Amgen Research Copenhagen

The emerging IPP toolkit 
with Carolyn Bertozzi, Ph.D., professor of Chemistry, Stanford

Induced Proximity: Reason for Optimism in Treating Cancer and Beyond 
with David Reese, M.D., executive vice president, Research and Development, Amgen

DNA Unlocked

DNA Unlocked, a 5-part podcast series about the twists and turns, highs and lows of the quest to generate insights from DNA sequencing that will solve some of the most challenging questions in the biology of disease.

Join host Ray Deshaies to go deep on how scientists are approaching the mountains of genomic data to tackle longstanding barriers to drug discovery, unlock cancer, and learn first-hand about exciting ideas 'coming around the bend.'

Stream all episodes


Episode List

Reshaping the Future 
with Amit V. Khera, M.D., MGH Center for Genomic Medicine

Unlocking the Genetics of Cancer 
with Angela Coxon, Ph.D., vice president of Oncology Research at Amgen

Beyond Genomics 
with Larry Gold, Ph.D., founder of Somalogic

Genetics vs. Biology 
with Saptarsi Haldar, M.D., vice president of Cardiometabolic Research at Amgen

Promise and the Potential 
with Richard Scheller, Ph.D., former chief scientific officer of 23andMe and former executive vice president of Research and Early Development at Genentech


 

Subscribe Below